Why is "Idarubicin" trending?
Latest news, Wikipedia summary, and trend analysis.
Trend Analysis
- Ranking position: #
- Date: 2026-07-15 17:34:31
This topic has appeared in the trending rankings 1 time(s) in the past year. While it does not trend frequently, its appearance suggests a renewed or concentrated surge of public interest.
Based on Wikipedia pageviews and search interest, this topic gained significant attention on the selected date.
Trend Insight
Idarubicin entered the ranking for the first time today at position #. This is its highest position ever recorded.
Trend History
This topic has appeared in the English Wikipedia rankings 1 time. It first appeared on 2026-07-15 and was most recently seen on 2026-07-15.
Wikipedia Overview
Idarubicin or 4-demethoxydaunorubicin is an anthracycline antileukemic drug. It inserts itself into DNA and prevents DNA unwinding by interfering with the enzyme topoisomerase II. It is an analog of daunorubicin, but the absence of a methoxy group increases its fat solubility and cellular uptake.
Similar to other anthracyclines, it also induces histone eviction from chromatin.
Related Topics
Trending Topic Today
Search Interest Perspective
-
Myopericarditis After Combined Idarubicin and Quizartinib in FLT3-ITD–Positive AML: - JACC Journals
-
High-dose cytarabine with idarubicin consolidation for acute myeloid leukemia in first complete remission: a randomized controlled trial - Nature
-
FLAG-based regimen delivers strong outcomes in subtype of acute myeloid leukemia - Medical Xpress
-
Cladribine, idarubicin, and cytarabine (CLIA) for patients with relapsed and/or refractory acute myeloid leukemia: A single-center, single-arm, phase 2 trial - Wiley & Sons
-
Idarubicin versus Epirubicin in Transarterial Chemoembolization for BCLC Stage B HCC (Radiology In A Minute) - RSNA Journals
-
Venetoclax, Cladribine, Idarubicin, Cytarabine Regimen Evaluated in AML, High-Risk MDS - docwirenews.com
-
Comparison of idarubicin and high-dose daunorubicin in the induction chemotherapy for AML – a phase III study - aml-hub.com
-
Idarubicin-transarterial chemoembolization combined with gemcitabine plus cisplatin for unresectable intrahepatic cholangiocarcinoma - Baishideng Publishing Group
-
Idarubicin, cytarabine, and nivolumab in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a single-arm, phase 2 study - The Lancet
-
Exploring Cladribine, Idarubicin, and Ara-C: Initial Therapy for AML, with or without Sorafenib - Physician's Weekly
-
APOLLO: ATO-ATRA Improves Efficacy Over Standard ATRA + Chemotherapy in Newly Diagnosed High-Risk APL - dailynews.ascopubs.org
-
Venetoclax Plus High-Dose Cytarabine With or Without Idarubicin Well Tolerated in Pediatric AML - ashpublications.org
-
Heart Failure in AML: New Evidence Emerges - EMJ
-
Correction: Long term results of venetoclax combined with FLAG-IDA induction and consolidation for newly diagnosed and relapsed or refractory acute myeloid leukemia - Nature
-
Idarubicin-Loaded DEB-TACE plus Lenvatinib versus Lenvatinib for patients with advanced hepatocellular carcinoma: A propensity score-matching analysis - Wiley Online Library
-
Ponatinib with fludarabine, cytarabine, idarubicin, and granulocyte colony-stimulating factor chemotherapy for patients with blast-phase chronic myeloid leukaemia (MATCHPOINT): a single-arm, multicentre, phase 1/2 trial - The Lancet
-
Permissive Cardiotoxicity and Determination of Anthracycline Risk With Previous Anthracycline Exposure - JACC Journals
-
Anagrelide and idarubicin combination induces GSDME-mediated pyroptosis as a potential therapy for high-PDE3A acute myeloid leukemia - Nature
-
Modified conditioning regimen with idarubicin followed by autologous hematopoietic stem cell transplantation for invasive B-cell non-Hodgkin’s lymphoma patients - Nature
-
Carbon-based ruthenium nanomaterial-based electroanalytical sensors for the detection of anticancer drug Idarubicin - Nature
-
Researchers Identify Potential Predictors of Rash During AML Induction Therapy - The American Journal of Managed Care
-
ATRA/ATO Regimen Improves EFS in Newly Diagnosed, High-risk APL - OncLive
-
Phase II study of cladribine, idarubicin, and ara‐C (CLIA) with or without sorafenib as initial therapy for patients with acute myeloid leukemia - Wiley Online Library
-
Induction with idarubicin, cytarabine, and cladribine in patients with ND AML: Results from a phase III trial - aml-hub.com
-
ATO-ATRA Outperforms Chemo-ATRA in High-Risk APL - Cancer Therapy Advisor
-
Idarubicin-intensified haploidentical HSCT with GvHD prophylaxis of ATG and basiliximab provides comparable results to sibling donors in high-risk acute leukemia - Nature
-
ASH 2023: Tailoring Treatment in AML - Cancer Therapy Advisor
-
Drug combination helps children with acute promyelocytic leukemia avoid conventional chemotherapy - National Cancer Institute (.gov)
-
Phase Ib CAVEAT trial: Venetoclax plus chemotherapy in elderly patients with NPM1 or IDH1/IDH2-mutated de novo AML - aml-hub.com
-
American Journal of Hematology | Blood Research Journal - Wiley Online Library
-
Venetoclax Plus FLAG-IDA Elicits High and Durable Responses in Newly Diagnosed AML - OncLive
-
Combination therapy yields strong long-term overall response rate in newly diagnosed acute myeloid leukemia patients - UT MD Anderson
-
Cytarabine/idarubicin - Springer Nature Link
-
Cytarabine/etoposide/idarubicin - Springer Nature Link
-
JACC: CardioOncology Expert Panel Recommends Equivalence Ratios For Some Chemotherapy Drugs Post Childhood Cancer - American College of Cardiology
-
ATRA Plus Arsenic Trioxide Feasible for Acute Promyelocytic Leukemia - Cancer Therapy Advisor
-
Addition of gemtuzumab ozogamicin to induction chemotherapy - aml-hub.com
-
FLA-IDA with or without venetoclax in patients with relapsed/refractory acute myeloid leukemia - aml-hub.com
-
Drug-induced hypersensitivity syndrome with rapid hematopoietic reconstitution during treatment for acute myeloid leukemia - Haematologica
-
Addition of midostaurin to frontline 7+3: A case report - aml-hub.com
-
FLAG-IDA for acute myeloid leukemia - aml-hub.com
-
P-glycoprotein in primary acute myeloid leukemia and treatment outcome of idarubicin/cytosine arabinoside-based induction therapy - Nature
-
Idarubicin improves blast cell clearance during induction therapy in children with AML: results of study AML-BFM 93 - Nature
-
Teva recalls one lot of leukemia med after finding particulates in vial - Fierce Pharma
-
All-Trans Retinoic Acid and Arsenic Trioxide in High-Risk Acute Promyelocytic Leukemia - The ASCO Post
-
Antineoplastics/voriconazole - Springer Nature Link
-
Venetoclax with intensive chemotherapy for younger patients with ND AML, or MDS - aml-hub.com
-
Combination of Venetoclax Plus FLAG-IDA Leads to High Response Rates in Newly Diagnosed AML - docwirenews.com
-
Venetoclax plus decitabine vs intensive chemotherapy for young patients with ND AML - aml-hub.com
-
Venetoclax Plus FLAG-IDA Induction and Consolidation for AML - The ASCO Post
-
Arsenic Trioxide for Acute Promyelocytic Leukemia Reduces Risk for Relapse - Cancer Therapy Advisor
-
FLAG+/-Ida Linked to Better Outcomes in Non-Favorable–Risk AML - Cancer Therapy Advisor
-
Pharmacokinetics and tissue distribution of idarubicin-loaded solid lipid nanoparticles after duodenal administration to rats - Wiley Online Library
-
Long-term results from the phase III randomized study of attenuated arsenic trioxide and ATRA for patients with acute promyelocytic leukemia - aml-hub.com
-
Venetoclax combined with FLAG-IDA induction and consolidation in newly diagnosed acute myeloid leukemia - Wiley Online Library
-
Venetoclax plus FLAG-IDA as frontline and salvage therapy in patients with ND and R/R AML - aml-hub.com
-
Optimizing induction regimens in younger patients with AML: The UK AML19 trial - aml-hub.com
-
Antineoplastics - Springer Nature Link
-
FLAG-Ida or daunorubicin combined with clofarabine in high-risk acute myeloid leukemia – data from the AML17 trial - aml-hub.com
-
England | Bristol | Drug overdose 'was manslaughter' - BBC
-
After Taking Lupron, I Would Never Give It To A Healthy Child - thefederalist.com
Why This Topic Is Trending
This topic has recently gained attention due to increased public interest. Search activity and Wikipedia pageviews suggest growing global engagement.
Search Interest & Related Topics
Search interest data over the past 12 months indicates that this topic periodically attracts global attention. Sudden spikes often correlate with major news events, public statements, or geopolitical developments.